Filing Flows › Amneal Pharmaceuticals (AMRX) › Q2 2026 › vs Q2 2025
Amneal Pharmaceuticals (AMRX) Q2 2026 vs Q2 2025 (year over year)
Amneal Pharmaceuticals's revenue rose $71.7M (+10%) from $725M in Q2 2025 to $796M in Q2 2026. The biggest changes: Affordable Medicines +$56.5M (+13%); Specialty +$21.3M (+17%); AvKARE −$6.1M (-4%). Gross margin 42.0% against 39.5% (+2.5 pts).
Amneal Pharmaceuticals, Q2 2026: revenue $796M (+10% year over year), operating margin 16.3%, net earnings $57.7M, operating cash flow −$21.2M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 42.0% | 39.5% | +2.5 pts |
| Operating margin | 16.3% | 15.4% | +0.9 pts |
| Net margin | 7.2% | 3.1% | +4.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Affordable Medicines | $490M | $433M | $56.5M | +13% |
| AvKARE | $157M | $163M | −$6.1M | -4% |
| Specialty | $149M | $128M | $21.3M | +17% |
| Revenue | $796M | $725M | $71.7M | +10% |
| Gross profit | $335M | $286M | $48.3M | +17% |
| Cost of revenue | $462M | $438M | $23.4M | +5% |
| Operating profit | $130M | $111M | $18.4M | +17% |
| Operating expenses | $205M | $175M | $29.9M | +17% |
| Pre-tax earnings | $71.0M | $51.7M | $19.3M | +37% |
| Other expense, net | $58.8M | $59.7M | −$882K | -1% |
| Research & development | $39.0M | $48.0M | −$8.9M | -19% |
| SG&A | $149M | $124M | $24.5M | +20% |
| Other operating costs | $17.0M | $2.7M | $14.3M | +541% |
| Net earnings | $57.7M | $22.4M | $35.2M | +157% |
| Minority interests | $12.0M | $13.2M | −$1.2M | -9% |
| Income tax | $1.4M | $16.1M | −$14.7M | -91% |
| Operating cash sources | $89.3M | −$53.1M | $142M | — |
| Share-based compensation | $10.4M | $8.3M | $2.1M | +26% |
| Cash used in operations | $21.2M | −$83.8M | $105M | — |
| Working capital & other | $89.3M | −$53.1M | $142M | — |
Questions
How much did Amneal Pharmaceuticals's revenue grow year over year in Q2 2026?
Amneal Pharmaceuticals's revenue rose $71.7M (+10%) from $725M in Q2 2025 to $796M in Q2 2026.
What drove Amneal Pharmaceuticals's revenue change in Q2 2026?
Affordable Medicines +$56.5M (+13%); Specialty +$21.3M (+17%); AvKARE −$6.1M (-4%).